The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
MUMBAI, December 12, 2013 /PRNewswire/ --
A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective
Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of drug gable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.
(Logo: http://photos.prnewswire.com/prnh/20130128/590935 )
Bharat Book Bureau presents the report entitled "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" published in October 2013 describes chances and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. (http://www.bharatbook.com/healthcare-market-research-reports/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-cells-emerging-opportunities-for-the-biopharmaceutical-industry.html)
Access to drug gable, IP-protected and validated new targets are a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.
The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.
Benefits from the report:
- Identify players in the field, from industry and academia;
- Find out which TCR technologies are valued by Big Parma and Biotech;
- Understand the value of intracellular antigens targeted by the TCR;
- Recognize the challenges of TCR-based therapeutics and their solutions;
- Learn which TCR-based therapeutics are attractive for partnering;
- Find out which TCR therapeutic approaches are not yet tapped.
Table of Contents
- Executive Summary
- Introduction
- The T-Cell Receptor
- TCR Fusion Proteins
- Altor Bioscience
- Overview
- Financing history
- IP protection
- Partnering
- STAR technology
- Binding affinity of scTCRs
- Manufacturing of STAR molecules
- Targets for scTCRs
- Generation of scTCRs
- Other applications of STAR molecules
- STAR pipeline
- ALT-801
- Preclinical characterization of ALT-801
- Clinical results of studies with ALT-801
- Ongoing clinical studies with ALT-801
- Safety of ALT-801 in clinical studies
- Clinical immunogenicity of ALT-801
- Clinical pharmacokinetics of ALT-801
- ALT-802
- Assessment
- Immunocore
- Corporate development of Immunocore
- Stability and solubility of TCRs
- Affinity of monoclonal TCRs (mTCR)
- Effector function for mTCR
- Target discovery for mTCRs
- Preclinical experience with mTCRs
- ImmTAC clinical lead program
- Partnering
- Assessment
- TCR-Like (TCRL) Antibodies
Eureka Therapeutics & Memorial Sloan-Kettering Cancer Center
Target of TCRL antibody
Generation of TCRL antibody
Preclinical characterization of TCRL antibody
Intellectual property
Corporate background
Assessment
Applied Immune Technologies
Corporate background
Financial history
Cancer target
Technologies
Viral targets
Generation of TCRL antibodies
Assessment
- TCR-Transfected T-Cells
Adaptimmune
Corporate Background
Overview of manufacturing
The TCR engineering process
TCR-transfected T-cells versus CAR-transfected T-clls
Clinical R&D in cancer
Clinical HIV study with TCR T-cells
Assessment
Academic Studies with TCR-Transfected T-Cells
- Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells
CAR-modified T-cells for cancer
Background
Clinical experience with CAR-modified T-cells
The three generations of CAR-Modified T-cells
Assessment
Autologous CAR-Modified T-Cells
Novartis & The University of Pennsylvania
Celgene & bluebird bio & Baylor College of Medicine
Kite Parma
Allogeneic CAR-Modified T-Cells
Cellectis
CAR-Modified Induced Pluripotent Stem Cells
- Tumor-Infiltrating Lymphocytes (TILs)
Lion Biotechnologies
- Opportunity Analysis for TCR-based Products and Technologies
- References
- Corporate R&D Pipelines
Adaptimmune
Altor Bioscience
Immunocore
Lion Biotechnologies
Request for sample pages: http://www.bharatbook.com/RequestSample.asp?pid=230115
For more information on the report: http://www.bharatbook.com/healthcare-market-research-reports/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-cells-emerging-opportunities-for-the-biopharmaceutical-industry.html
Related Reports:
Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013
Global Cancer Monoclonal Antibodies Pipeline Analysis
The 2013-2018 Outlook for Autoimmune Disease Therapeutics in India
Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
T-Cell Lymphomas - Pipeline Review, H2 2013
Related Category:
About Bharat Book Bureau
Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.
Contact us:
Poonam
Bharat Book Bureau
USA/Canada - 1-866-279-8368 (Toll free)
India: +91-22-27810772, 27810773
Blog: http://blog.bharatbook.com
E: [email protected]
W: http://www.bharatbook.com
SOURCE Bharat Book Bureau
Share this article